| Title |
Imidapril
|
|---|---|
| Published in |
Drugs, September 2012
|
| DOI | 10.2165/00003495-200767090-00008 |
| Pubmed ID | |
| Authors |
Dean M. Robinson, Monique P. Curran, Katherine A. Lyseng-Williamson |
| Abstract |
Imidapril (Tanatril), through its active metabolite imidaprilat, acts as an ACE inhibitor to suppress the conversion of angiotensin I to angiotensin II and thereby reduce total peripheral resistance and systemic blood pressure (BP). In clinical trials, oral imidapril was an effective antihypertensive agent in the treatment of mild to moderate essential hypertension. Some evidence suggests that imidapril also improves exercise capacity in patients with chronic heart failure (CHF) and reduces urinary albumin excretion rate in patients with type 1 diabetes mellitus. Imidapril was well tolerated, with a lower incidence of dry cough than enalapril or benazepril, and is a first choice ACE inhibitor for the treatment of mild to moderate essential hypertension. |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 18% |
| Student > Bachelor | 7 | 18% |
| Researcher | 4 | 11% |
| Student > Master | 3 | 8% |
| Student > Doctoral Student | 2 | 5% |
| Other | 5 | 13% |
| Unknown | 10 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 39% |
| Nursing and Health Professions | 3 | 8% |
| Chemistry | 2 | 5% |
| Sports and Recreations | 2 | 5% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 5 | 13% |
| Unknown | 10 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2024.
All research outputs
#4,369,297
of 25,373,627 outputs
Outputs from Drugs
#667
of 3,464 outputs
Outputs of similar age
#31,114
of 188,964 outputs
Outputs of similar age from Drugs
#222
of 1,461 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,964 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 1,461 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.